Our compounds are first-in-class therapeutic proteins for the treatment of chronic pain and hearing loss.
HB-086 and HB-097 are recombinant drug candidates of human Meteorin and human Cometin. This family of proteins have unique therapeutic properties and act on sensory nerve cells and their supporting glia cells.
Hoba Therapeutics has been selected by The European Commission’s European Innovation Council (EIC) as a start-up champion. Hoba will receive grant funding and qualifies for further equity investment from EIC Accelerator.
August 2019 - New Publication
Antihyperalgesic effects of Meteorin in the rat chronic constriction injury model: a replication study.
Danish Hoba Therapeutics and a consortium of national and international partners have secured the ongoing development of the drug candidate HB-086 for treatment of neuropathic pain with an investment from Innovation Fund Denmark (IFD) of DKK18.4M (≈€2.5M), and thereby a major step towards clinical trials